Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -112.56% is 28% above its 5-year average of -155.29%, around the middle of its 5-year range (-745.55%–656.29%).
As of the fiscal period ended Wednesday, December 31, 2025. 34.38% above its 12-month average of -171.53%.
Annual fiscal-year return on equity; no daily interpolation.
RETURN ON EQUITY (ROE)
-112.56%
RETURN ON EQUITY (ROE) AVG TTM
-171.53%
RETURN ON EQUITY (ROE) AVG 3Y
-210.62%
RETURN ON EQUITY (ROE) AVG 5Y
-155.29%
RETURN ON EQUITY (ROE) AVG 10Y
-112.11%
RETURN ON EQUITY (ROE) AVG 15Y
-88.79%
RETURN ON EQUITY (ROE) AVG 20Y
-53.00%
CURRENT VS TTM AVG
+34.38%
CURRENT VS 3Y AVG
+46.56%
CURRENT VS 5Y AVG
+27.52%
CURRENT VS 10Y AVG
-0.40%
CURRENT VS 15Y AVG
-26.77%
CURRENT VS 20Y AVG
-112.37%
SECTOR MEDIAN · HEALTHCARE
10.89%
median of 79 covered companies
CURRENT VS SECTOR MEDIAN
-1133.61%
vs the sector median at left
HCA Healthcare, Inc.
Market Cap
$87.16B
Return on Equity (ROE)
-112.56%
TTM Avg
-171.53%
3Y Avg
-210.62%
5Y Avg
-155.29%
Market Cap
$81.51B
Return on Equity (ROE)
11.06%
TTM Avg
13.69%
3Y Avg
14.71%
5Y Avg
14.93%
Market Cap
$78.57B
Return on Equity (ROE)
11.15%
TTM Avg
14.72%
3Y Avg
15.95%
5Y Avg
23.11%
Market Cap
$100.24B
Return on Equity (ROE)
-219.24%
TTM Avg
-189.06%
3Y Avg
-180.53%
5Y Avg
3473.86%
Market Cap
$73.82B
Return on Equity (ROE)
15.05%
TTM Avg
11.32%
3Y Avg
12.19%
5Y Avg
12.83%
Market Cap
$69.46B
Return on Equity (ROE)
14.19%
TTM Avg
10.21%
3Y Avg
8.16%
5Y Avg
6.40%
Market Cap
$109.30B
Return on Equity (ROE)
9.70%
TTM Avg
9.71%
3Y Avg
8.51%
5Y Avg
8.44%
Market Cap
$60.57B
Return on Equity (ROE)
75.01%
TTM Avg
168.34%
3Y Avg
-32.99%
5Y Avg
148.52%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| HCA Healthcare, Inc. (HCA) | $87.16B | -112.56% | -171.53% | -210.62% | -155.29% |
| Elevance Health Inc. (ELV)vs › | $81.51B | 11.06% | 13.69% | 14.71% | 14.93% |
| Regeneron Pharmaceuticals, Inc. (REGN)vs › | $78.57B | 11.15% | 14.72% | 15.95% | 23.11% |
| McKesson Corporation (MCK)vs › | $100.24B | -219.24% | -189.06% | -180.53% | 3473.86% |
| Cigna Corporation (CI)vs › | $73.82B | 15.05% | 11.32% | 12.19% | 12.83% |
| GSK plc (GSK)vs › | $103.56B | 25.19% | 26.90% | 55.97% | 45.70% |
| Boston Scientific Corporation (BSX)vs › | $69.46B | 14.19% | 10.21% | 8.16% | 6.40% |
| Medtronic plc (MDT)vs › | $109.30B | 9.70% | 9.71% | 8.51% | 8.44% |
| Cencora, Inc. (COR)vs › | $60.57B | 75.01% | 168.34% | -32.99% | 148.52% |
| Becton, Dickinson and Company (BDX)vs › | $60.00B | 4.72% | 6.60% | 6.50% | 6.42% |
ROE
-112.6%
ROA
7.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -112.56% |
| 2024-12-31 | -230.49% |
| 2023-12-31 | -295.49% |
| 2022-12-31 | -203.94% |
| 2021-12-31 | -745.55% |
| 2020-12-31 | 656.29% |
| 2019-12-31 | -124.82% |
| 2018-12-31 | -76.51% |
| 2017-12-31 | -32.56% |
| 2016-12-31 | -39.58% |
| 2015-12-31 | -28.02% |
| 2014-12-31 | -23.75% |
| 2013-12-31 | -18.81% |
| 2012-12-31 | -16.61% |
| 2011-12-31 | -29.85% |
| 2010-12-31 | -10.12% |
| 2009-12-31 | -11.73% |
| 2008-12-31 | -6.56% |
| 2007-12-31 | -8.29% |
| 2006-12-31 | -9.11% |
| 2005-12-31 | 29.28% |
| 2004-12-31 | 28.27% |
| 2003-12-31 | 21.45% |
| 2002-12-31 | 14.61% |
| 2001-12-31 | 18.61% |
| 2000-12-31 | 6.63% |
| 1999-12-31 | 13.17% |
| 1998-12-31 | 6.21% |
| 1997-12-31 | -4.21% |
| 1996-12-31 | 17.48% |
